Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Gilead's current market cap attributes little value to its growth potential. I present Bear/Base/Bull valuation scenarios and the implied value of growth. Gilead's proven record for sophisticated, ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the positions showed up on publicly ...

The Current Market Value of Gilead is about $120B. The Enterprise Value of Gilead more or less equates to its Market Value since the Cash on the Balance Sheets is negated by the Debt on the Balance ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead Sciences, Inc. (NASDAQ:GILD) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day ...